Login / Signup

Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies: ISOO/MASCC/ASCO Guideline.

Valeria MercadanteSiri Beier JensenDerek K SmithKari BohlkeJessica BaumanMichael T BrennanRobert P CoppesNiels JessenNarinder K MalhotraBarbara A MurphyDavid I RosenthalArjan VissinkJonn WuDeborah P SaundersDouglas E Peterson
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
For patients who receive radiation therapy for head and neck cancer, tissue-sparing radiation modalities should be used when possible to reduce the risk of salivary gland hypofunction and xerostomia. Other risk-reducing interventions that may be offered during radiation therapy for head and neck cancer include bethanechol and acupuncture. For patients who develop salivary gland hypofunction and/or xerostomia, interventions include topical mucosal lubricants, saliva substitutes, and sugar-free lozenges or chewing gum. For patients with head and neck cancer, oral pilocarpine and oral cevimeline, acupuncture, or transcutaneous electrostimulation may be offered after radiation therapy.Additional information can be found at www.asco.org/supportive-care-guidelines.
Keyphrases